Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, par value $0.005 per share
-
Shares outstanding
-
7.7M
-
Number of holders
-
14
-
Total 13F shares, excl. options
-
517K
-
Shares change
-
+467K
-
Total reported value, excl. options
-
$566K
-
Value change
-
+$511K
-
Number of buys
-
6
-
Number of sells
-
-2
-
Price
-
$1.10
Significant Holders of Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share (ERNA) as of Q3 2025
15 filings reported holding ERNA - Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share as of Q3 2025.
Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share (ERNA) has 14 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 517K shares
of 7.7M outstanding shares and own 6.71% of the company stock.
Largest 10 shareholders include Corient Private Wealth LLC (438K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (30.9K shares), GEODE CAPITAL MANAGEMENT, LLC (20.5K shares), VANGUARD GROUP INC (11.1K shares), Sippican Capital Advisors (10K shares), Tower Research Capital LLC (TRC) (5.18K shares), BlackRock, Inc. (820 shares), ASSETMARK, INC (133 shares), EverSource Wealth Advisors, LLC (116 shares), and MORGAN STANLEY (77 shares).
This table shows the top 14 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.